Kyle R Duchman1, Yubo Gao2, Benjamin J Miller3. 1. Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, 01015 JPP, Iowa City, IA 52242, USA. Electronic address: kyle-duchman@uiowa.edu. 2. Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, 01015 JPP, Iowa City, IA 52242, USA. Electronic address: yubo-gao@uiowa.edu. 3. Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, 01015 JPP, Iowa City, IA 52242, USA. Electronic address: benjamin-j-miller@uiowa.edu.
Abstract
BACKGROUND: The current study aims to determine cause-specific survival in patients with high-grade osteosarcoma while reporting risk factors for decreased survival out to 10 years. METHODS: The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify all patients diagnosed with high-grade osteosarcoma from 1991 to 2010. Patient, tumor, and county-level socioeconomic measures were analyzed to determine prognostic factors for survival. RESULTS: Cause-specific 10-year survival for patients with local/regional disease at the time of diagnosis was 65.8%, compared to 24.0% for patients with metastatic disease. Multivariate analysis revealed metastatic disease at presentation, age≥60 years, male sex, axial location, and size≥10cm as independent risk factors for decreased cause-specific survival at 10 years. Patients with the lowest socioeconomic status had a disproportionate frequency of metastatic disease and large tumors at presentation as compared to more affluent patients. CONCLUSIONS: Patients with high-grade osteosarcoma have decreased cause-specific survival at 10 years when metastatic at diagnosis, patient age≥60 years, male sex, axial tumor location, and tumors measuring≥10cm. Patients living in low socioeconomic counties present more frequently with metastatic disease and large tumors. Public health efforts should focus on identifying patients with osteosarcoma prior to metastasis.
BACKGROUND: The current study aims to determine cause-specific survival in patients with high-grade osteosarcoma while reporting risk factors for decreased survival out to 10 years. METHODS: The Surveillance, Epidemiology, and End Results (SEER) Program database was used to identify all patients diagnosed with high-grade osteosarcoma from 1991 to 2010. Patient, tumor, and county-level socioeconomic measures were analyzed to determine prognostic factors for survival. RESULTS: Cause-specific 10-year survival for patients with local/regional disease at the time of diagnosis was 65.8%, compared to 24.0% for patients with metastatic disease. Multivariate analysis revealed metastatic disease at presentation, age≥60 years, male sex, axial location, and size≥10cm as independent risk factors for decreased cause-specific survival at 10 years. Patients with the lowest socioeconomic status had a disproportionate frequency of metastatic disease and large tumors at presentation as compared to more affluent patients. CONCLUSIONS:Patients with high-grade osteosarcoma have decreased cause-specific survival at 10 years when metastatic at diagnosis, patient age≥60 years, male sex, axial tumor location, and tumors measuring≥10cm. Patients living in low socioeconomic counties present more frequently with metastatic disease and large tumors. Public health efforts should focus on identifying patients with osteosarcoma prior to metastasis.
Authors: Daniel R Evans; Alexander L Lazarides; Mark M Cullen; Julia D Visgauss; Jason A Somarelli; Dan G Blazer; Brian E Brigman; William C Eward Journal: Ann Surg Oncol Date: 2021-05-20 Impact factor: 5.344
Authors: Roelof Koster; Orestis A Panagiotou; William A Wheeler; Eric Karlins; Julie M Gastier-Foster; Silvia Regina Caminada de Toledo; Antonio S Petrilli; Adrienne M Flanagan; Roberto Tirabosco; Irene L Andrulis; Jay S Wunder; Nalan Gokgoz; Ana Patiño-Garcia; Fernando Lecanda; Massimo Serra; Claudia Hattinger; Piero Picci; Katia Scotlandi; David M Thomas; Mandy L Ballinger; Richard Gorlick; Donald A Barkauskas; Logan G Spector; Margaret Tucker; D Hicks Belynda; Meredith Yeager; Robert N Hoover; Sholom Wacholder; Stephen J Chanock; Sharon A Savage; Lisa Mirabello Journal: Int J Cancer Date: 2017-12-23 Impact factor: 7.396